Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions ...
Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...
Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...
From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...
As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...
Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.
A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results